- Home
- LZ vs AVBP Comparison
LZ vs AVBP Comparison
Compare LZ & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZ
- AVBP
- Stock Information
- Founded
- LZ 2001
- AVBP 2021
- Country
- LZ United States
- AVBP United States
- Employees
- LZ N/A
- AVBP N/A
- Industry
- LZ EDP Services
- AVBP
- Sector
- LZ Technology
- AVBP
- Exchange
- LZ Nasdaq
- AVBP NYSE
- Market Cap
- LZ 1.5B
- AVBP 862.8M
- IPO Year
- LZ 2021
- AVBP 2024
- Fundamental
- Price
- LZ $9.00
- AVBP $20.99
- Analyst Decision
- LZ Hold
- AVBP Strong Buy
- Analyst Count
- LZ 9
- AVBP 8
- Target Price
- LZ $8.64
- AVBP $39.00
- AVG Volume (30 Days)
- LZ 1.8M
- AVBP 467.6K
- Earning Date
- LZ 08-06-2025
- AVBP 08-13-2025
- Dividend Yield
- LZ N/A
- AVBP N/A
- EPS Growth
- LZ 72.11
- AVBP N/A
- EPS
- LZ 0.17
- AVBP N/A
- Revenue
- LZ $690,777,000.00
- AVBP N/A
- Revenue This Year
- LZ $8.18
- AVBP $66.25
- Revenue Next Year
- LZ $7.23
- AVBP N/A
- P/E Ratio
- LZ $52.98
- AVBP N/A
- Revenue Growth
- LZ 3.25
- AVBP N/A
- 52 Week Low
- LZ $5.33
- AVBP $15.47
- 52 Week High
- LZ $10.60
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- LZ 54.78
- AVBP 44.84
- Support Level
- LZ $8.48
- AVBP $22.12
- Resistance Level
- LZ $8.83
- AVBP $23.27
- Average True Range (ATR)
- LZ 0.21
- AVBP 1.43
- MACD
- LZ -0.01
- AVBP -0.38
- Stochastic Oscillator
- LZ 59.78
- AVBP 7.84
About LZ LegalZoom.com Inc.
LegalZoom.com Inc is an online provider of services that meet the legal needs of small businesses and consumers in the United States. The company also offers services that include ongoing compliance and tax advice and filings, business licenses, accounting, virtual mailbox and e-signature solutions, trademark filings, and estate plans.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.